Associated Papers
An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis.
Gertsman I et al.
Jci Insight, 2019
Computing disease-linked SOD1 mutations: deciphering protein stability and patient-phenotype relations.
Kumar V et al.
Scientific Reports, 2017
28680046 (PubMed )
Supplement: 41598_2017_4950_MOESM1_ESM.pdf
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.
Miller TM et al.
The Lancet. Neurology, 2013
Misfolded superoxide dismutase-1 in CSF from amyotrophic lateral sclerosis patients.
Zetterström P et al.
Journal of Neurochemistry, 2011
Multiple missense mutations in the diazepam binding inhibitor (DBI) gene identified in schizophrenia but lack of disease association.
Niu N et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics, 2004
Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes.
Andersen PM et al.
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003
Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment.
Pramatarova A et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience, 2001
Select a paper to view details